Kimberly A. Kraynyak, Ph.D.
Affiliations: | 2009 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
DNA vaccine, HIVGoogle:
"Kimberly Kraynyak"Mean distance: 23748
Parents
Sign in to add mentor| David B. Weiner | grad student | 2009 | Penn | |
| (Modulation of the immune response at systemic and mucosal sites by DNA vaccine adjuvants in HIV and influenza models.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jacobson JM, Zahrieh D, Strand CA, et al. (2022) Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevention Research (Philadelphia, Pa.). OF1-OF11 |
| Jacobson JM, Zahrieh D, Strand CA, et al. (2022) Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevention Research (Philadelphia, Pa.) |
| Kraynyak KA, Blackwood E, Agnes J, et al. (2022) SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. The Journal of Infectious Diseases |
| Vonderheide RH, Kraynyak KA, Shields AF, et al. (2021) Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. Journal For Immunotherapy of Cancer. 9 |
| Tebas P, Yang S, Boyer JD, et al. (2020) Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. Eclinicalmedicine. 100689 |
| Shore ND, Morrow MP, McMullan T, et al. (2020) CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Hasan Y, Furtado L, Tergas A, et al. (2020) A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. International Journal of Radiation Oncology, Biology, Physics |
| Aggarwal C, Cohen RB, Morrow MP, et al. (2020) Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines. 8 |
| Reardon DA, Brem S, Desai AS, et al. (2020) INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal of Clinical Oncology. 38: 2514-2514 |
| Aggarwal C, Cohen RB, Morrow MP, et al. (2020) Abstract CT126: A synthetic DNA plasmid encoding HPV6 E6 and E7 proteins in patients with HPV6-associated aerodigestive lesions Tumor Biology |